GITR ligation enhances functionality of tumor-infiltrating T cells in hepatocellular carcinoma.
Antibodies, Monoclonal
/ immunology
B-Lymphocytes
/ immunology
CD4-Positive T-Lymphocytes
/ immunology
CD8-Positive T-Lymphocytes
/ immunology
Carcinoma, Hepatocellular
/ immunology
Cell Line, Tumor
Female
Glucocorticoid-Induced TNFR-Related Protein
/ immunology
Humans
Immunotherapy
/ methods
Liver Neoplasms
/ immunology
Lymphocytes, Tumor-Infiltrating
/ immunology
Male
Middle Aged
RNA, Messenger
/ immunology
T-Lymphocytes, Regulatory
/ immunology
CD357
GITR
HCC
PD1
TNFRSF18
Treg
cancer immunotherapy
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
15 08 2019
15 08 2019
Historique:
received:
12
09
2018
revised:
09
01
2019
accepted:
14
01
2019
pubmed:
6
2
2019
medline:
4
12
2019
entrez:
6
2
2019
Statut:
ppublish
Résumé
No curative treatment options are available for advanced hepatocellular carcinoma (HCC). Anti-PD1 antibody therapy can induce tumor regression in 20% of advanced HCC patients, demonstrating that co-inhibitory immune checkpoint blockade has therapeutic potential for this type of cancer. However, whether agonistic targeting of co-stimulatory receptors might be able to stimulate anti-tumor immunity in HCC is as yet unknown. We investigated whether agonistic targeting of the co-stimulatory receptor GITR could reinvigorate ex vivo functional responses of tumor-infiltrating lymphocytes (TIL) freshly isolated from resected tumors of HCC patients. In addition, we compared GITR expression between TIL and paired samples of leukocytes isolated from blood and tumor-free liver tissues, and studied the effects of combined GITR and PD1 targeting on ex vivo TIL responses. In all three tissue compartments, CD4
Identifiants
pubmed: 30719701
doi: 10.1002/ijc.32181
pmc: PMC6619339
doi:
Substances chimiques
Antibodies, Monoclonal
0
Glucocorticoid-Induced TNFR-Related Protein
0
RNA, Messenger
0
TNFRSF18 protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1111-1124Informations de copyright
© 2019 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
Références
Lancet. 2017 Jun 24;389(10088):2492-2502
pubmed: 28434648
Cancer Res. 2017 Mar 1;77(5):1108-1118
pubmed: 28122327
J Clin Oncol. 2014 Apr 1;32(10):1020-30
pubmed: 24590637
Cancer Res. 2009 Feb 1;69(3):1037-45
pubmed: 19155305
Eur J Cancer. 2016 Nov;67:1-10
pubmed: 27591414
Gastroenterology. 2008 May;134(6):1752-63
pubmed: 18471552
Oncoimmunology. 2017 Aug 30;6(12):e1371896
pubmed: 29209572
Nat Rev Immunol. 2010 May;10(5):328-43
pubmed: 20414206
FASEB J. 2007 Aug;21(10):2442-54
pubmed: 17360848
J Clin Invest. 2009 Mar;119(3):551-64
pubmed: 19229109
Blood. 2008 Nov 1;112(9):3735-43
pubmed: 18689545
J Biol Chem. 2008 Mar 28;283(13):8202-10
pubmed: 18230609
Cancer Res. 2008 Jul 15;68(14):5948-54
pubmed: 18632650
Lancet. 2017 Oct 21;390(10105):1853-1862
pubmed: 28822576
J Exp Med. 2013 Aug 26;210(9):1685-93
pubmed: 23897982
Oncoimmunology. 2015 May 29;4(12):e1051297
pubmed: 26587321
Hum Antibodies. 2017;25(3-4):87-109
pubmed: 28085016
Sci Transl Med. 2018 Jan 31;10(426):
pubmed: 29386357
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
J Transl Med. 2014 Feb 07;12:36
pubmed: 24502656
Nat Med. 2007 May;13(5):579-86
pubmed: 17417651
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
J Clin Oncol. 2015 Jun 20;33(18):2013-20
pubmed: 25800770
Oncoimmunology. 2015 Mar 19;4(6):e1008355
pubmed: 26155417
PLoS Pathog. 2015 Dec 03;11(12):e1005270
pubmed: 26633181
Hepatology. 2013 Jan;57(1):183-94
pubmed: 22911397
Proc Natl Acad Sci U S A. 2013 Nov 26;110(48):19501-6
pubmed: 24218606
Cancer Immunol Immunother. 2010 Sep;59(9):1367-77
pubmed: 20480365
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
Gastroenterology. 2017 Oct;153(4):1107-1119.e10
pubmed: 28648905
Cancer Immunol Res. 2013 Nov;1(5):320-31
pubmed: 24416730
Cancer Cell. 2016 Sep 12;30(3):369-371
pubmed: 27622328
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
Mol Aspects Med. 2008 Feb-Apr;29(1-2):130-43
pubmed: 18061252
N Engl J Med. 2017 Mar 16;376(11):1015-1026
pubmed: 28212060
Nat Med. 2016 Jun;22(6):679-84
pubmed: 27111280
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Blood. 2007 Jul 1;110(1):201-10
pubmed: 17371945
Am J Transplant. 2015 Sep;15(9):2431-42
pubmed: 25943855
N Engl J Med. 2013 Jul 11;369(2):134-44
pubmed: 23724846
Br J Cancer. 2015 Jun 9;112(12):1911-20
pubmed: 26057582
Lancet. 2017 Dec 2;390(10111):2461-2471
pubmed: 28993052
Immunity. 2009 Jun 19;30(6):899-911
pubmed: 19464196